Level C· Early human research exploring benefitsProspective StudyEurope PMC

Recent Innovations and Advances in Arteriovenous Fistula Creation: A Narrative Review

Lazcano-Etchebarne C., Aboian E., Strosberg D., Sadaghianloo N., Schwartz AW., Ho B.

Prospective Study on Autoimmune Research, published in Vasc Investig Ther (2025) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Vasc Investig Ther (2025)
Reported sample size
—
Source database
Europe PMC
PMID
40417719
PMCID
PMC12103191
DOI
10.4103/vit.vit_2_25
Citations
1

Abstract (original English)

Arteriovenous fistulae (AVF) are the gold standard for vascular access among patients requiring hemodialysis; however, AVF have high primary failure rates. Novel approaches and technologies to improve AVF patency include modifications to open approaches, such as the radial artery deviation and reimplantation fistula, and percutaneous approaches, such as the endovascular AVF. Despite these advances, these modifications are limited in reducing neointimal hyperplasia, stenosis, or thrombosis, and thus have limited capacity to improve AVF maturation and utilization; as such, vascular access requires continued innovation. Emerging strategies to prevent neointimal hyperplasia include drug-embedded and bioresorbable perivascular wraps. Increased rates of AVF failure among women highlight sex differences in the biology of AVF maturation and suggest additional targets to improve outcomes. Other advances in understanding the biology of AVF maturation suggest potentialized approaches for patients, including immune system modulation and stem cell therapies. Although these emerging technologies may improve AVF maturation and utilization, longer-term patency and freedom from complications such as central vein stenosis and dialysis access associated distal ischemia emphasize the critical need for continued scientific inquiry and technological development to optimize vascular access.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research